openPR Logo
Press release

Anti-Thrombin III Testing Market is Driven by Increasing Demand of Coagulation Testing for Anti-Thrombin III by End Users

05-23-2017 03:52 PM CET | IT, New Media & Software

Press release from: TMR - Research Reports

Anti-Thrombin III Testing Market is Driven by Increasing Demand

Anti-thrombin III is a naturally occurring inhibitor of blood coagulation that regulates the coagulation cascade. Anti-thrombin III is the type of serine protease inhibitor that inhibits the production of thrombin and other activated serine protease coagulation systems such as factor Xa, IXa and kallikrein. It is an α2-globulin member of the Serpin group and commonly synthesized in liver and is found in plasma and extra vascular sites. Anti-thrombin III influences the inflammatory processes via inhibition of actin polymerization. Testing for the Anti-thrombin II factor is helpful for the patients with recurrent deep vein thrombosis and pulmonary emboli are treated with the anti-thrombin III. In addition, anti-thrombin III testing is also used to treat the conditions such as arterial and venous thrombosis.

Browse through Anti-Thrombin III Testing Market report to know what factors will shape the market by 2023: http://www.transparencymarketresearch.com/anti-thrombin-testing-market.html

The market of anti-thrombin III can be segmented on the basis of:

By Application
Immunoassays
Dry Chemistry
Chromogenic Substrates
DNA Probes
Biosensors
Monoclonal and Polyclonal Antibodies
Microcomputers
Others

By End Users
Hospitals
Physician Offices
Commercial Labs and Private Labs
Ambulatory Care Centers
Others

The anti-thrombin III market is majorly driven by increasing demand of coagulation testing for anti-thrombin III by end users such as hospitals and physician offices in developed geographies such as North America and Europe. In addition, consistent introduction of novel anti-thrombin III testing methods further drives the growth of the market. Several companies are offering effective and innovative anti-thrombin III testing techniques which would stimulate the market growth. For example, Siemens AG offers Berichrom Antithrombin III (A) reagent that effectively used for the inhibition of the thrombin factor. In addition, the company also offers Sysmex CA-600 Systems that provides efficient clotting, immunologic detection and chromogenic methods and provides easy to use features for the laboratory settings. Thus, this factor would in turn enhance the number of patients utilizing the anti-thrombin III testing methods hence drives the market growth. However, strict regulatory environment and high cost of anti-thrombin III will restrain the anti-thrombin III market growth.

Geographically, North America dominates the global market for Anti-thrombin III. The accelerated growth in North America for anti-thrombin III is mainly attributed to the rising demand of coagulation testing among the patient population coupled with increasing incidence of blood related problems in this region. This factor would in turn establish the healthy to develop the growth of the market hence drives the market growth. Europe is considered as the second largest market of anti-thrombin III owing to the launch of innovation and novel anti-thrombin III testing methods by key players of the market. Launch of new anti-thrombin III testing methods would in turn increase the uptake of these methods which would stimulates the market growth of anti-thrombin III in European region. In addition, India, South East Asia and China are the geographically emerging market for anti-thrombin III and considered to grow with the highest CAGR in near future. Cost effective production environment for biotechnology and pharmaceutical companies compared to developed countries like the U.S. and Europe will attract many biotechnology companies to increase their investment in Asia-Pacific region. Moreover, countries such as India and China would consider as the biggest market for anti-thrombin III due to the high demand for anti-thrombin III testing among the patient population in these regions.

Get accurate market forecast and analysis on the Anti-Thrombin III Testing Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5258

Various key players contributing to the global Anti-thrombin III market comprises Siemens AG, Trinity Biotech PLC, Sysmex Corporation and others.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Anti-Thrombin III Testing Market is Driven by Increasing Demand of Coagulation Testing for Anti-Thrombin III by End Users here

News-ID: 547644 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for III

STEIGER DYNAMICS launches LEET III HTPC Chassis
REDWOOD CITY (December 27th, 2021) – STEIGER DYNAMICS just released the third iteration of its critically acclaimed LEET HTPC case. Except for a few subtle but elegant changes in design, LEET III Chassis shares the same one-piece, hand-brushed, full-aluminum shell that made its predecessors so iconic. Accompanied by the 7” front LED display that features our own LEET Monitor app, and full open-loop liquid cooling support, LEET III Chassis redefines
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Therapeutics - Pipelin …
Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is a progressive disorder that primarily affects brain and spinal cord (central nervous system). People with MPS III generally do not display features at birth, but they begin to show signs and symptoms of this disorder during early childhood. Affected children often initially have delayed speech and behaviour problems. Download the sample report @ https://www.pharmaproff.com/request-sample/1146 In later stages of this disorder, people
Global Antithrombin III Deficiency Testing Market
The Antithrombin III Deficiency Testing Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. Antithrombin deficiencies are mainly divided into two types: type I and type II. The type I antithrombin deficiency is characterized by an inadequate amount of normal antithrombin present in
EXCEEMO Industrial SATA III SSD
Extremely impressive performance, the highest reliability and guaranteed fixed BOM - all in one service package for industrial customers EXCEEMO, the memory and storage specialist from Landsberg am Lech, presents the industrial 2.5“ SATA III Solid-State-Drives with ultra-fast read/write transfer speed of up to 555MB/515MB per second and proven long-term reliability. The noiseless, energy-efficient and particularly robust solid state drives are available both in standard grade (0°/+70°C-MLC/SLC) and in industrial
BioFocus extends collaboration with Usher III Initiative
BioFocus announced today that it has expanded a collaboration with the Usher III Initiative, Inc., a non-profit organization focused on developing treatments for Usher syndrome type III, a rare genetic disorder that causes the loss of hearing and vision. BioFocus and the Usher III Initiative began their collaboration in July 2010 with BioFocus performing an integrated drug discovery program encompassing medicinal chemistry, ADME and biological sciences, aiming at a
NewBlueFX Introduces “Video Essentials III” Effects Plugins
NewBlueFX Introduces “Video Essentials III” Effects Plugins The Video Editor’s Wish List of Tools & Techniques in One Package Video, Multimedia and Technology Editors LA JOLLA, CA (November 04, 2009)— NewBlue, Inc. today launched Video Essentials III, the third and latest offering in its best-selling Video Essentials series of video effects and transitions plugins. NewBlue Video Essentials III provides highly-practical video tools designed to solve everyday production issues. The collection includes Rolling Shutter,